Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O"™Neal Comprehensive Cancer Center, University of Alabama at Birmingham explains how measurement of minimal residual disease (MRD) is evolving as an endpoint in clinical trials.
MRD Evolving as an Endpoint in Clinical Trials @End_myeloma @uabmedicine
